All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Epcoritamab in combination with rituximab + lenalidomide approved by the FDA for patients with R/R FL
On November 18, 2025, the U.S. Food and Drug Administration (FDA) approved epcoritamab, a T-cell engaging bispecific antibody, in combination with rituximab + lenalidomide for the treatment of adult patients with relapsed/refractory (R/R) follicular lymphoma (FL).1 This approval is based on results from the open-label, phase III EPCORE FL-1 (NCT05409066) trial, following previous accelerated approval by the FDA for epcoritamab monotherapy for the treatment of R/R FL after ≥2 prior lines of systemic therapy.1
EPCORE FL-11
- Results from the EPCORE FL-1 trial showed that epcoritamab + rituximab + lenalidomide (n = 243) reduced the risk of disease progression or death by 79% (hazard ratio [HR], 0.21; 95% confidence interval [CI], 0.13–0.33; p < 0.0001) compared with rituximab + lenalidomide (n = 245).
- The median progression-free survival was not reached with epcoritamab + rituximab + lenalidomide vs 11.2 months with rituximab + lenalidomide.
- The overall response rate was 89% and 74%, and the complete response rate was 74% and 43% in the epcoritamab- + rituximab + lenalidomide and rituximab + lenalidomide arms, respectively.
- The safety profile of epcoritamab + rituximab + lenalidomide was consistent with the known safety profile of the individual agents.
Data from the EPCORE FL-1 trial will be presented at the upcoming 67th American Society of Hematology (ASH) Meeting and Exposition, December 6–9, 2025, Orlando, US.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In your experience, does lisocabtagene maraleucel offer a durable, potentially curative remission with a one-time infusion in second-line large B-cell lymphoma?
